RWE Raises FY21 Earnings Forecast

RWE Aktiengesellschaft (RWEOY.PK), on Friday, said it has revised its financial guidance for the full year 2021.

The company now expects 2021 adjusted EBITDA to be in the range of EUR3.0 billion - EUR3.4 billion, compared to the previously communicated range of EUR2.65 billion to EUR3.05 billion.

Adjusted EBITDA of the core business is projected to range between EUR2.15 billion and EUR2.55 billion, up from the prior guidance range of EUR1.8 billion - EUR2.2 billion.

Further, the company lifted its fiscal 2021 adjusted EBIT to EUR1.5 billion - EUR1.9 billion from the prior expectation of EUR1.15 billion - EUR1.55 billion and adjusted net income outlook to EUR1.05 billion - EUR1.40 billion from the prior guidance range of EUR0.75 billion - EUR1.10 billion.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Cyltezo, originally approved in August 2017, is both biosimilar to, and interchangeable with Humira for Cyltezo's approved uses. The Food and Drug Administration may be planning to allow people to receive Covid-19 vaccine booster shot that is different from the initial dose, reports indicate. The agency is likely to make the announcement on mix and match approach on coronavirus booster vaccines on Wednesday. The move will be part of FDA's expected authorization of boosters for the Moderna and Johnson & Johnson vaccines. Drug major Johnson & Johnson on Tuesday raised again its forecast for fiscal 2021 earnings and sales, which are above market view, after reporting higher results in the third quarter. The company's quarterly adjusted earnings also beat market estimates. In pre-market activity on the NYSE, JNJ shares were gaining around 1.24 percent to trade at $162.10.
Follow RTT